Worth reading
56In focus
Scored from 4 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
249
¥ million (year-on-year change in operating loss)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending June 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit△1,358
Ordinary income△1,307
Net income△1,308
Selling, general and administrative expenses¥301 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Basic research expenses¥226 million
- Clinical development expenses¥830 million
- Selling, general and administrative expenses¥301 million
- Non-operating income and expenses (primarily foreign exchange gains)¥50 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- Cost of the CBP501 Phase 3 clinical trial¥4.5–5.0 billion
- Basic research expenses and SG&A expenses¥100–150 million per quarter
New initiatives
- Continuation of the application and regulatory activities for initiating the European Phase 3 clinical trial of CBP501
- Consideration of a new clinical development strategy for CBS9106 based on basic research following its return
- Joint drug discovery research using AI with INTAGE Healthcare
- Joint research with the University of Shizuoka on an IDO/TDO dual inhibitor, together with alliance activities by the Pharma Valley Center
Number of employees
Number of Employees19
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Operating profit | △1,358 |
| Ordinary income | △1,307 |
| Net income | △1,308 |
| Selling, general and administrative expenses | ¥301 million |
| Breakdown of Factors Affecting the Change | Factors Basic research expenses / Amount ¥226 million, Factors Clinical development expenses / Amount ¥830 million, Factors Selling, general and administrative expenses / Amount ¥301 million, Factors Non-operating income and expenses (primarily foreign exchange gains) / Amount ¥50 million |
| Number of employees | Number of Employees 19 / Changes during the period and hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | Item Cost of the CBP501 Phase 3 clinical trial / Value ¥4.5–5.0 billion, Item Basic research expenses and SG&A expenses / Value ¥100–150 million per quarter |
| New initiatives | Continuation of the application and regulatory activities for initiating the European Phase 3 clinical trial of CBP501, Consideration of a new clinical development strategy for CBS9106 based on basic research following its return, Joint drug discovery research using AI with INTAGE Healthcare, Joint research with the University of Shizuoka on an IDO/TDO dual inhibitor, together with alliance activities by the Pharma Valley Center |
Items this document does not state (21)
Net SalesGross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Clinical development expenses increased due to the application to initiate the Phase 3 clinical trial of CBP501 and related regulatory activities, particularly those concerning the manufacture and formulation of the drug. Below operating income, the Company primarily recorded a ¥50 million foreign exchange gain.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.